id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-345517-ji4cet51	Duarte de Araújo, António Manuel Silva	Copd: will there be room for nebulisers after the current covid-19 pandemic?	2020-09-16		.txt	text/plain	1338	73	45	They are not regularly recommended for chronic disease management in COPD, because there is no evidence of superiority of nebulisers in patients who are able to use portable inhaler devices properly.6 However, when prescribed, patients are usually satisfied with nebulised therapy, and it is often preferred by those who have been recently hospitalised. In a recent systematic review and meta-analysis, high doses of nebulised budesonide during hospitalisation, seemed to be non-inferior to systemic corticosteroids, in the treatment of COPD acute exacerbations.9 Nebulised corticosteroids can also be preferable versus oral prednisolone in patients with diabetes mellitus or with heart failure, because of the mineralocorticoid effects and fluid retention related to systemic corticosteroids. A subgroup of COPD patients is known to present chronic bronchial infection, and the use of antibiotics can be associated with reduction of bacterial load.10 Low doses of nebulised antibiotics can provide higher tissue concentration with fewer bacterial-resistance related issues.	./cache/cord-345517-ji4cet51.txt	./txt/cord-345517-ji4cet51.txt